Biodesix (BDSX) AI Stock Analysis

• Market Cap: $156.35M
• Dividend Yield: N/A
• Average Volume (3M): 107.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: 22.29%
• EPS Growth: 31.93%
• Country: US
• Employees: 273
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.49
• Shares Outstanding: 9,858,358
• 10 Day Avg. Volume: 48,205
• 30 Day Avg. Volume: 107,552
• PEG Ratio: 0.05
• Price to Book (P/B): -20.83
• Price to Sales (P/S): 0.58
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 2.30
• Enterprise Value/Gross Profit: 2.83
• Enterprise Value/Ebitda: -9.25
• 1Y Price Target: $30.00
• Price Target Upside: 89.16% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): -3.16
• Revenue Forecast (FY): $108.68M

• Rating: 56 Neutral
• Price Target: $14.50 ▼(-8.58% Downside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (ongoing losses, cash burn, and a stressed balance sheet with negative equity). Offsetting this are constructive earnings-call signals (strong 2026 growth guidance, high gross margins, and momentum toward adjusted EBITDA positivity) and a favorable technical trend, though overbought indicators add near-term risk.

Positive Factors

Accelerating revenue growth and 2026 guidance

Sustained double‑digit top‑line growth and explicit 2026 guidance indicate improving commercial traction and a scalable demand base. This growth trajectory provides a durable revenue runway that can absorb continued SG&A investment and supports progression toward sustained operating leverage over the next 2–6 months.

Industry-leading gross margins (~80%)

Very high unit economics suggest strong structural profitability potential as volumes scale. Sustaining ~80% gross margins provides a durable cushion to fund sales expansion and R&D while helping adjusted EBITDA convert to sustained profitability once fixed-cost absorption improves.

Commercial buildout with expanding sales coverage

A materially larger, rapidly ramping salesforce increases durable addressable market penetration and test adoption. Historical rep productivity (coverage breakeven in ~3 months) implies repeatable unit economics, supporting sustained volume growth and higher ASPs over multiple quarters.

Negative Factors

Weakened balance sheet and elevated leverage

Negative equity and sizable debt materially reduce financial flexibility and increase refinancing risk. A stressed capital structure constrains strategic optionality, raises interest and covenant sensitivity, and heightens reliance on external funding to sustain commercial expansion over the medium term.

Persistent negative operating and free cash flow

Ongoing cash burn necessitates repeated financing and limits self‑funding of growth initiatives. Until operating cash flow turns sustainably positive, the company remains exposed to capital‑market conditions, which can delay strategic investments or force dilutive financings during adverse market cycles.

Clinical timing delay for ALTITUDE readout

Delay of a key clinical readout pushes a material potential commercial and guideline catalyst out over the longer horizon. This extends uncertainty around reimbursement, guideline adoption and market expansion for pipeline products, slowing realization of projected incremental revenues.

Biodesix Business Overview & Revenue Model

Company Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

How the Company Makes Money

Biodesix generates revenue primarily through the sale of its diagnostic tests and related services. The company offers a range of tests that analyze biomarkers to guide treatment decisions in oncology, with a specific emphasis on lung cancer. Revenue is derived from healthcare providers and institutions that utilize these tests as part of their patient management protocols. Additionally, Biodesix may engage in partnerships with pharmaceutical companies, which can lead to collaborations that enhance its product offerings and expand its market reach. These partnerships can provide milestone payments and royalties, further contributing to the company's income. Furthermore, reimbursement from insurance payers for the diagnostic tests can also be a significant source of revenue, as it ensures that healthcare providers are compensated for utilizing Biodesix's services.

Biodesix Financial Statement Overview

Summary

Revenue growth is improving, but the overall financial profile remains high-risk: the company is still deeply loss-making, free cash flow is negative, and the balance sheet weakened with stockholders’ equity turning negative alongside sizable debt—limiting financial flexibility.

Income Statement

Revenue growth has improved meaningfully, accelerating to ~10.4% in 2025 versus low-to-mid single digit growth in prior years, showing better commercial traction. However, profitability remains weak: the company is still deeply loss-making with a ~-39.8% net margin in 2025 and negative EBITDA margins across all periods provided. While losses have narrowed versus 2022–2024, the business has not yet demonstrated a path to sustained operating profitability in the reported results.

Balance Sheet

Leverage has risen and the balance sheet weakened materially in 2025 as stockholders’ equity turned negative (-$2.5M) alongside ~$72.9M of total debt, which is a key risk signal and reduces financial flexibility. Prior years show equity was positive but declining and debt-to-equity moved sharply higher over time (from ~0.5x in 2021 to ~13.3x in 2023 before equity flipped negative). Overall, the capital structure appears stressed for a diagnostics company still generating net losses.

Cash Flow

Cash generation remains a major concern: operating cash flow and free cash flow are negative in every year shown, including 2025 (operating cash flow -$23.3M; free cash flow -$23.5M). The burn rate improved substantially from 2024 (operating cash flow -$48.6M; free cash flow -$51.9M), but free cash flow still deteriorated versus 2024 on a growth basis (about -19.6%). Overall, the company is relying on external funding to support operations until cash flows turn sustainably positive.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	88.50M	71.32M	49.09M	38.21M	54.51M
Gross Profit	66.59M	55.75M	36.08M	24.06M	23.99M
EBITDA	-21.88M	-29.22M	-37.10M	-51.53M	-35.47M
Net Income	-35.27M	-42.93M	-52.15M	-65.45M	-43.16M
Balance Sheet
Total Assets	87.48M	97.24M	99.10M	92.91M	76.10M
Cash, Cash Equivalents and Short-Term Investments	18.99M	26.25M	26.28M	43.09M	32.71M
Total Debt	72.85M	61.98M	60.69M	31.85M	10.01M
Total Liabilities	89.94M	76.37M	94.52M	72.30M	56.37M
Stockholders Equity	-2.46M	20.88M	4.58M	20.61M	19.73M
Cash Flow
Free Cash Flow	-23.53M	-51.88M	-45.93M	-48.51M	-30.77M
Operating Cash Flow	-23.27M	-48.65M	-22.87M	-44.97M	-28.22M
Investing Cash Flow	-403.00K	-3.44M	-23.06M	-3.53M	-2.55M
Financing Cash Flow	16.42M	52.05M	29.13M	58.88M	1.26M

Biodesix Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.86
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDSX, the sentiment is Positive. The current price of 15.86 is above the 20-day moving average (MA) of 13.21, above the 50-day MA of 10.38, and above the 200-day MA of 8.05, indicating a bullish trend. The MACD of 1.81 indicates Negative momentum. The RSI at 81.58 is Negative, neither overbought nor oversold. The STOCH value of 76.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BDSX.

Biodesix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BNR	57 Neutral	$245.91M	-0.99	-19.87%	―	5.44%	72.17%
BDSX	56 Neutral	$156.35M	-1.46	-302.55%	―	22.29%	31.93%
PRPO	56 Neutral	$46.46M	-92.19	-9.76%	―	30.95%	59.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SERA	48 Neutral	$77.19M	-4.85	-47.69%	―	1.06%	22.41%
VNRX	47 Neutral	$26.68M	-3.41	―	―	14.48%	36.83%